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Abstract 
Owen Rowell 
MRes  
Development of Novel Nutrapharmaceuticals Combining the Anti-
Oxidant and Anti-Inflammatory Properties of n-3 Fatty Acids with 
a Nitric Oxide Donor – a Potential New Preventative Strategy for 
Heart Disease 
Atherosclerosis is a cardiovascular disease which forms plaques which 
narrow the arteries, restricting blood flow and thus increasing blood 
pressure.  As this can lead to more serious conditions, such as myocardial 
infarction, it is important that atherosclerosis is treated to prevent 
dangerous levels of atherosclerotic plaques forming. 
The aim of this project was to create a library of novel PUFA-NO 
conjugates which would contain the combined beneficial cardioprotective 
and anti-inflammatory qualities of both groups. 
Synthesis of aliphatic-aminothiol conjugates has been achieved using both 
acid chloride (N-decanoyl cysteamine (Compound 1), N-decanoyl L-
cysteine ethyl ester (compound 3)) and peptide coupling based reactions, 
and full characterisation has been achieved. 
The nitration stage of synthesis was achieved using tert-butyl nitrite and 
„fuming‟ NO as the nitrating agents. Successful nitration was determined 
by MS analysis and by use of the Griess reaction as a colourimetric test to 
determine the ability of the synthesised compounds (S-nitroso N-decanoyl 
cysteamine (compound 7), S-nitroso N-oleoyl cysteamine (compound 8)) 
to release nitric oxide. 
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Abbreviations 
 
ACE  Angiotensin converting enzyme 
CAD   Coronary Artery Disease 
CVD  Cardiovascular Disease 
DHA  Docosa Hexaenoic Acid 
DiPEA  N,N-Diisopropylethylamine 
EDRF  Endothelium Derived Relaxing Factor 
EPA  Eicosapentaenoic Acid 
HDL  High Density Lipoprotein 
HMG-CoA 3-hydroxy-3-methylglutaryl-coenzyme A 
Hobt  Hydroxybenzotriazole 
LDL  Low Density Lipoprotein 
MS  Mass spectrometry 
NMR  Nuclear magnetic resonance 
NO  Nitric Oxide 
NOS  Nitric Oxide Synthase 
NSAID Non-Steroidal Anti-Inflammatory Drug 
PUFA  Polyunsaturated Fatty Acid 
 6 
SFA  Saturated Fatty Acid 
SNO  S-Nitrosothiol 
TBTU (2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
tetrafluoroborate) 
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1.1.  Cardiovascular Disease 
 
Cardiovascular disease is the leading cause of death in adults in the 
United Kingdom. There were almost two hundred thousand related deaths 
in 2006 attributed to cardiovascular disease, which accounted for almost 
one third of all deaths in the U.K. that year (British Heart Foundation, 
2008).  The term refers to a range of conditions that affect arteries and 
the heart such as myocardial infarction, angina, coronary artery disease, 
chronic heart failure, pulmonary hypertension and atherosclerosis. 
Causes of cardiovascular disease vary, but can include genetic factors, 
obesity, sedentary lifestyle, diabetes and smoking (World Health 
Organisation, 2009). 
Treatment for cardiovascular disease involves many stages, requiring 
management such as undertaking lifestyle changes, stress reduction, 
dietary changes, surgical intervention and drugs (World Health 
Organisation, 2009). 
Secondary treatments for cardiovascular disease, which have been shown 
to reduce the risk of cardiovascular events, include increasing fruit and 
vegetable intake and partaking in moderate levels of physical activity on a 
regular basis (Ignarro at al., 2007).  Whilst regular excessive consumption 
of alcohol is linked to an increase in a range of heart conditions and 
disease (Klatsky, 2007), some research (Wollin & Jones, 2001) has 
indicated that moderate intake of alcohol (red wine) can actually confer 
beneficial cardioprotective effects. 
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Dietary interventions can also take place in the form of reducing saturated 
fatty acids in the diet and giving an omega rich polyunsaturated fatty acid 
diet.  Such a diet is a low risk alternative to drug therapy which can 
prevent the need for surgery and can reduce the effects of cardiovascular 
disease (CVD) (Patil and Gisleroed, 2006). 
Current NHS treatment guidelines for cardiovascular disease include the 
following management: antiplatelet treatment can be administered as 
primary prevention, usually in patients with a 10 year risk of 20% or 
greater for cardiovascular disease, in the form of daily 75 mg doses of 
aspirin, or 75 mg daily doses of Clopidogrel in cases of aspirin intolerance.  
The same treatment can be administered as a secondary preventative of 
CVD where the patient has a recognized cardiovascular disease, such as 
myocardial infarction, angina, stroke or peripheral arterial disease (NHS, 
2009(a)). 
Someone defined as „at high risk‟ of cardiovascular disease under NHS 
guidelines is someone who falls under the following categories: being 
aged 75 years or older, suffers from established CVD, has family history of 
hypercholesterolaemia, has type 2 diabetes and aged 40 or more.  Drug 
intervention is recommended for high risk CVD patients and treatment can 
include statin treatment as a primary treatment, antiplatelet prescription 
as previously mentioned and a lifestyle management plan to minimise 
further risk factors (NHS, 2009(b)). 
 
 
 
 
 
 
 
 9 
1.2. Atherosclerosis 
 
Known as the hardening of the arteries, atherosclerosis is the “leading 
cause of mortality and morbidity in the developed world” and it is believed 
it could also become the leading worldwide killer through its 
“manifestations such as cardiovascular disease and stroke” (Young and 
Libby, 2007). 
Atherosclerosis was initially believed to stem from high cholesterol levels 
caused by fat intake. In the late 1970s, developments (Hansson, 2009) 
were made in the field of atherosclerosis pathogenesis leading to a re-
evaluation of atherosclerosis as a chronic inflammatory condition (Ross, 
1999). 
Atherosclerosis is a chronic inflammatory condition caused by a build-up 
of lipids, such as cholesterol, and macrophages on the endothelial tissue 
of arteries.  These accumulations begin as „fatty streaks‟ but can harden 
and form plaques, effectively narrowing the artery, reducing blood flow 
and causing high blood pressure.  Complications can arise from the 
atherosclerotic plaques, such as a rupture or calcification of the plaque, 
which could severely restrict blood flow (Young and Libby, 2007). 
Causes of atherosclerosis are similar to those of cardiovascular disease in 
general, in that poor diet, lack of exercise and smoking can all be 
contributing factors. 
Treatments for atherosclerosis are varied but can include statin treatment, 
lifestyle changes, diet and dietary supplements, and surgery, such as 
angioplasty or coronary artery bypass (Young and Libby, 2007). 
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Statins are a series of drugs which inhibit cholesterol synthesis in the liver 
(Schoen at al., 2007) and are shown to reduce low density lipoprotein 
cholesterol levels and thus lower the incidence of ischaemic heart disease 
greatly (Law at al., 2003).  Trials have shown in some cases that high 
intensity statin treatments can also lead to atherosclerosis regression 
(Nissen at al., 2006). 
The chemical structures of some example statins are shown in figure 1: 
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Figure 1:  Chemical structures of selected statins. 
Lovastatin has been used as a treatment to lower serum cholesterol by 
inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate 
limiting enzyme for cholesterol biosynthesis (Zhu at al., 1992).  All statins 
work in this manner, by inhibiting HMG-CoA reductase, and are selected 
for use based on ability to normalise serum cholesterol levels and cost 
(Chong at al., 2001).  
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The development of atherosclerosis occurs in stages, initially changing 
from a normal artery to an early atheroma.  The early atheroma can 
generate one of two outcomes, a „stable‟ plaque and a „vulnerable‟ plaque. 
These „vulnerable‟ plaques contain a larger number of inflammatory cells 
and lipids than the „stable‟ plaque and also have a thin fibrous cap (Young 
and Libby, 2007).  The thin fibrous cap is prone to rupture, which leads to 
thrombus formation which can result in a healed, but much narrowed, 
artery or have the devastating consequence of acute myocardial 
infarction. 
Atherosclerotic plaque formations can result in varying complications, 
such as plaque calcification which confers pipe-like rigidity to the vessel 
wall, leading to fragility.  A rupture or ulceration of a vulnerable plaque 
can lead to vessel blockage, causing an infarction, or alternatively the 
thrombosis can be incorporated into the plaque, further narrowing an 
artery.  The vessel wall can be weakened by the fibrous plaque exerting 
constant pressure on the nearby medial tissue, which could cause dilation 
of the artery and ultimately form an aneurysm (Young and Libby, 2007). 
As high LDL cholesterol and abnormal lipid levels lead to a greater chance 
of atherosclerosis developing, finding effective means of lowering levels is 
becoming increasingly important.  Changes in lifestyle factors can reduce 
risk, such as replacing a sedentary lifestyle with moderate exercise on a 
regular basis, stopping smoking and reducing alcohol intake, as well as 
other dietary factors, such as reduced saturated fat intake. 
Studies have shown that statin treatment for at-risk individuals can 
placate and even, in some cases, regress atherosclerotic plaques. The 
ASTEROID trial (Nissen at al., 2006) demonstrated that, with a high 
intensity therapy using the statin rosuvastatin, a significant regression of 
atherosclerosis can result. 
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Studies have been undertaken in recent years to determine to what 
extent increased polyunsaturated fatty acid consumption affects the 
progression of atherosclerosis.  The JELIS trial (Yokoyama at al., 2007) 
found against a control group taking statins, a trial group taking both 
statins and PUFA showed a significant decrease of 19% fewer major 
coronary events. 
Other studies, such as the GISSI trial (Marchioli at al., 1999) have also 
demonstrated control groups taking PUFA supplements are less likely to 
suffer fatal coronary events from complications, such as atherosclerosis 
and cardiovascular disease. 
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1.3. Nitric Oxide 
 
Nitric oxide is one of the simplest and smallest molecules, yet a very 
important one in the human body, as it is implicated in key biological 
functions.  Chemically, it is a diatomic molecule with an unpaired electron 
on the nitrogen, causing it to be a radical, and has a bond order of 2.5.  It 
is a relatively stable molecule despite this and resists dimerisation to 
dinitrogen dioxide, N2O2.  A key factor accounting for this is delocalisation 
of the unpaired electron between the nitrogen and the oxygen atoms, 
rather than being localised on the nitrogen (Butler and Nicholson, 2003). 
In human cells, the nitric oxide synthase enzymes, commonly known as 
NOS, catalyse the oxidation of L-arginine causing release of nitric oxide 
(Al-Sa‟Doni and Ferro, 2000).  The nitric oxide produced is then used to 
activate guanylyl cyclase which leads to vasorelaxant effects.  Figure 2 
shows this in more detail below. 
 
Figure 2: NO release via NOS enzymes activating guanylyl cyclase to give vasorelaxant effects, Al-
Sa‟Doni and Ferro, 2000 
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There are three types of NOS enzymes, two of which are dependent on 
elevated levels of Ca2+ and the third of which acts independent of Ca2+ 
levels.  Neuronal NOS, known as nNOS, and endothelial NOS (eNOS) are 
dependent on raised Ca2+ levels (Fleming and Busse, 1999) and are 
constitutive enzymes in their respective areas (Pagliaro, 2003) whilst it is 
inducible NOS (iNOS) that is independent from Ca2+ and induced by 
“inflammatory cytokines or ischemic stimulus” (Pagliaro, 2003). 
Endothelial NOS activity has been implicated in vasodilation and 
maintenance of vascular tone, indeed a deficiency of the eNOS enzyme 
has been related to cases of hypertension (Awolesi at al., 1995).   Links 
have also been made between eNOS and the inhibition of platelet 
aggregation and adhesion and inhibition of smooth muscle cell 
proliferation (Marletta, 1993) 
Nitric oxide (NO) has been recognised as an endothelial derived relaxing 
factor (EDRF) (Furchgott and Vanhoutte, 1989) and was shown to relax 
the smooth muscle in the arterial vessel in patients afflicted by 
atherosclerotic plaques, resulting in increased blood flow.  A simplified 
view of the biological mechanism of action is illustrated in figure 3. 
 
Figure 3:  EDRF action of NO (Butler and Williams, 1993) 
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In the body, nitric oxide is generated in the endothelium and can diffuse 
into the vascular smooth muscle, whereby it acts as a vasorelaxant.  One 
of the reasons it can diffuse like this is due to its small molecular size 
(Butler and Nicholson, 2003).  Nitric oxide generated in the endothelium is 
constitutively expressed by eNOS, although certain factors can still affect 
the amount of NO produced.  It has been reported that in cases of high 
levels of oxidised low density lipoprotein there is a reduced expression of  
eNOS enzyme whilst in cases of exercised subjects, the eNOS enzyme is 
expressed in greater amount, leading to more NO available for production 
(Harrison, 1997). 
Inhaled nitric oxide has been shown to have vasodilating effects in cases 
of pulmonary hypertension (Kovalchin at al., 1997).  In addition, it has 
long been known that S-nitrosothiols (Ignarro at al., 1981) can give the 
same vasodilation effects by means of nitric oxide release.  It has been 
reported that nitric oxide is present almost exclusively as S-
nitrosoglutathione in the human airway, which acts as an intermediary in 
the release of NO giving a bronchodilator effect (Nevin and Broadley, 
2002), which implicates nitric oxide or NO donors as potentially useful in 
the field of asthma treatment. 
Nitric oxide also has a role to play in cancer.  It has been shown that 
cancer cell lines of many different types of cancer, including lung, prostate 
and lung cancer, have their growth hindered by application of a NO 
donating drug (more specifically a NO donating non-steroidal anti-
inflammatory drug) (Bonavida at al., 2006).   Developments along these 
lines show that nitric oxide and nitric oxide donors could have an 
important role to play in developing new chemotherapeutic drugs.   In the 
body, macrophages produce nitrates, and the production of these nitrates 
is dependent on the availability of arginine.  The arginine-NO pathway is 
present in macrophages, thus Stuehr (et al. 1989) implied that nitric oxide 
is a natural cytotoxic agent and is synthesised by the body as a defence 
mechanism against foreign or abnormal cells. 
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When an atherosclerotic plaque ruptures, the result is the endothelium is 
damaged and sub-endothelial tissue is then exposed.  This exposed layer 
consists mainly of collagen and platelets interact strongly with this 
collagen, inducing shape change causing them to adhere and activate.  
This leads to fibrin aggregating over platelets; this process leads to 
closure of the rupture in the vessel, which, in atherosclerotic plaques, can 
cause dangerous vessel constriction (Rang and Dale, 1991).  Nitric oxide 
has been shown to inhibit this adhesion of fibrils and endothelial cells 
(Radomski at al., 1990) and thus can be of vital help in cases of 
atherosclerotic plaque rupture by avoiding dangerous constriction of the 
artery. 
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1.4. Fatty Acids 
 
Much of the study within the area of polyunsaturated fatty acids (PUFAs) 
has centred on the beneficial effects they can confer as an anti-
inflammatory agent with cardioprotective qualities. 
A saturated fatty acid (SFA) is a molecule with a polar carboxylic acid 
head with a long chain aliphatic hydrocarbon tail, denoted as saturated 
because each carbon is saturated with sp3 hybridised C-H bonds. As the 
chain is straight the molecule can be densely packed.  An example of a 
SFA is given in figure 4. 
O
HO
palmitic acid  
Figure 4: Example of a saturated fatty acid 
Polyunsaturated fatty acids are somewhat similar but differ to SFAs in key 
areas.  The carboxyl acid head of the molecule is the same, but the 
hydrocarbon chain differs in that it has multiple double bonds between 
adjacent carbons, C=C, such as the example in figure 5.  
Monounsaturated fatty acids also exist, the key difference between a 
monounsaturated fatty acid and a polyunsaturated fatty acid is that the 
monounsaturated fatty acid contains only one C=C bond. 
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O
HO
Docosahexaenoic acid
 
Figure 5: Cis conformation docosahexaenoic acid. 
 
The conformation means the cis-PUFA will not accumulate in the same 
manner as the straight trans molecules.  The puckering effect is caused by 
rigidity introduced by the C=C bond.  Eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) are denoted as n-3 PUFAs as the first double 
bond in the chain starts on the third carbon from the methyl end. 
Large scale controlled trials have given evidence that the omega-3 
polyunsaturated fatty acids EPA and DHA both confer cardioprotective 
effects (Lee at al., 2008).  These PUFAs can be taken as a measure to 
prevent the onset of arterial plaques and heart disease.  Indeed, it is 
reported that atherosclerotic plaques are stabilised by the n-3 PUFAs EPA 
and DHA, and believed that this stability effect leads to reduced 
cardiovascular incidents (Thies at al., 2003). 
Omega-3 PUFAs, such as EPA and DHA are essential fatty acids (Grundt 
and Nilsen, 2008) which the body is unable to generate itself, so must be 
obtained either in the diet (such as eating omega oil rich fish) or through 
supplements. 
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It is believed that the ratio of n-6 to n-3 PUFAs is very important as there 
is competition between the enzymatic pathways of both: an 
overabundance of either n-3 or n-6 will reduce the metabolic process of 
the other, which leads to a lack of its beneficial results.  Western diet is 
heavily weighted in favour of n-6 PUFAs, but many diets, such as oily fish, 
contain n-3 fatty acids in sufficient levels that increasing consumption of 
oily fish in the diet will go some way to rebalancing the n-3: n-6 ratio 
(Thies at al., 2003). 
Many human dietary intervention trials have been carried out with an aim 
to better understand the beneficial properties which n-3 polyunsaturated 
fatty acids confer.  As far back as 1989, the DART trial (Burr at al., 1989) 
showed that fish based fatty acids could provide a secondary means to 
preventing coronary heart disease. The MRFIT trial (Dolecek at al., 1991) 
displayed a control group taking fish derived n-3 PUFAs to suffer a 
reduced rate of mortality from coronary artery disease (CAD) and CVD. 
 
In the late 90s, the “Indian Experiment of Infarct Survival” (Singh at al., 
1997) published results indicating that a control group taking PUFA 
supplements had reduced incidence of cardiac events, such as non-fatal 
myocardial infarction and the SCIMO trial (von Schacky at al., 2001) 
produced encouraging results that patients taking fish oil based n-3 PUFA 
had less progression, and even a small amount of regression, of 
atherosclerotic plaques.  The GISSI trial (Marchioli at al., 1999) again 
demonstrated that patients taking PUFA supplements in a controlled 
intervention experienced decreased rate of non-fatal myocardial infarction 
and death.  As previously mentioned, the JELIS trial (Yokoyama at al., 
2007) showed that PUFA in conjunction with statin treatment results in a 
significantly reduced incidence of major coronary events. 
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Whilst these numerous intervention trials leave little doubt about the 
effectiveness of n-3 polyunsaturated fatty acids as cardioprotective 
agents, the manner in which they act as such is still the subject of much 
research. 
It is proposed that PUFAs can protect against cardiovascular disease via 
multiple methods, such as acting as an antiatherogenic agent, slightly 
lowering blood pressure, decreasing inflammatory response, inhibition of 
thrombosis, by decreasing susceptibility to arrhythmias and by improving 
endothelial function (Kris-Etherton at al., 2003). 
Omura (Omura at al. 2001) proposed that eicosapentaenoic acid caused 
enzymatic inducement of nitric oxide, via the eNOS cycle and activating 
endothelium dependent vasorelaxation. 
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1.5. Nitric Oxide Donors 
 
As nitric oxide confers beneficial effects, partly due to the EDRF, “direct 
delivery of NO is expected to be effective in the prevention and/or 
treatment” of various cardiovascular disorders (Herman and Moncada, 
2005).  The effect of nitric oxide applied to smooth muscle cells in this 
manner is to activate the guanylyl cyclase enzyme, which then catalyses 
the production of cyclic guanosine monophosphate (cGMP) from guanosine 
triphosphate, leading to smooth muscle relaxation (Levick, 2003).  The 
ability of NO donors to bypass the nitric oxide generating mechanism of 
the endothelium and deliver NO directly to the arterial walls (Butler and 
Williams, 1993) in need of vasorelaxation can make them potentially very 
useful. 
Glyceryl trinitrate, figure 6, is used in the treatment of angina (National 
Health Service, 2006) and has been known as a vasodilator for many 
years and acts as such by breaking down to release nitric oxide in vivo 
(Salvemini at al., 1993).  Two further nitric oxide donors are shown in 
figure 6, sodium nitroprusside and isosorbide mononitrate. 
ON+
O
-O
O
N+-O
O
O
N+
O-
O
Glyceryl Trinitrate
O N
---Fe
N
C
NC
N
C
N
C
N C
Sodium Nitroprusside
2Na+
2-
O
O
OH
O
N+
-O O
Isosorbide mononitrate  
Figure 6: Currently used NO donors. 
Isosorbide mononitrate is also used in the treatment of angina, preferred 
as a long term treatment to glyceryl trinitrate which is administered in 
cases of acute angina related pain.  Sodium nitroprusside has been used 
in hospitals in cases where there is an urgent need for vasodilation, but 
the drug is limited due to the difficulties in administering it, as well as the 
cyanide groups contained in the structure (McDowall at al., 1974). 
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As well as conventional nitric oxide donor drugs, there have been many 
studies (Keeble and Moore, 2002; Ongini at al., 2004; Martelli at al., 
2006) on developing nitric oxide hybrid drugs, where a NO donating 
moiety is stably attached to a clinically active drug.  The perceived 
advantages to this strategy are that the beneficial effects of NO are then 
incorporated into the current drug and in some cases can even reduce 
some of the negative side effects of the parent molecule. 
One such example would be of the NO-NSAID (non steroidal anti 
inflammatory drug) “NicOx” compounds, which were nitric oxide releasing 
aspirin derivative drugs.  As extended treatments of aspirin in 
cardiovascular cases can lead to unwanted side effects, such as 
gastrointestinal bleeding (Keeble and Moore, 2002), and NO has beneficial 
properties in this area which can counter the negative effect, the final 
drug was shown to retain the aspirin drug effect whilst minimising the 
negative side-effects.  In addition to conferring anti-inflammatory 
properties, NO-NSAIDs have also shown promise as a potential treatment 
for neurological conditions, such as Alzheimer‟s disease (Keeble and 
Moore, 2002). 
Nitric oxide releasing derivatives of statins are another example of the use 
of a hybrid NO donor compound.  As previously discussed in section 1.2, 
statins are beneficial and indeed a frontline treatment in high cholesterol 
related cardiovascular disease, and a nitric oxide releasing hybrid statin 
could offer further vasorelaxing properties to the drug in treatment of 
cardiovascular diseases such as atherosclerosis.  One such study of NO-
statin hybrids (Ongini at al., 2004) concluded that NO donor hybrid statins 
offered a multiple mechanism approach to treating atherosclerosis which 
could potentially give better results than normal statins. 
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Nitric oxide donating derivatives of salbutamol, which is used to treat 
chronic asthma, have been created and have been shown in studies to be 
more potent as a bronchodilator than the salbutamol parent molecule.  
NO-paracetamol has been shown to reduce the toxic effects of 
paracetamol in the liver, (Keeble and Moore, 2002) giving two further 
instances whereby a NO donating moiety attached to a parent molecule 
with an established pharmacological effect can prove beneficial. 
Two types of cardiovascular drugs, ACE-inhibitors and sartans, treat 
hypertension by acting upon the renin angiotensin system in differing 
ways to prevent a hypertensive effect.  NO donating derivatives of both 
types of drug have been synthesised and tested; S-nitrosocaptopril (being 
the S-nitrosylated form of the ACE-inhibitor captopril) enhances the 
pharmacological effect of the parent drug by means of the NO donor 
(Martelli at al., 2006).  Nitric oxide donor hybrids of sartans have also 
enhanced their effect as cardiovascular drugs and gave the hybrid drug 
greater vasorelaxing properties (Martelli at al., 2006). 
There are a wide range of molecules which act as NO donors (Chakrapani 
at al., 2008), such as the nitro, nitroso and oxime C-NO donors illustrated 
below in figure 7: 
R
N O    R R
N
OH
       
R N
O
O  
Figure 7: Example of nitroso, oxime and nitro C-NO donors.                             
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In addition to this, there are also a range of O-NO donors, such as the 
aforementioned examples of glyceryl trinitrate and isosorbide 
mononitrate.   Figure 8 displays the structure of glyceryl mononitrate 
which also acts as an O-NO nitric oxide donor (Martelli at al., 2006). 
O
N
+
O
O
-
OH
HO
  
Figure 8: Glyceryl mononitrate. 
Transition metal complexes such as sodium nitroprusside shown in figure 
9 can also act as NO donors (Martelli at al., 2006). 
O N
---
Fe
N
N
NN
N
Na
+
2Na
+
2-
 
Figure 9: sodium nitroprusside 
There are many S-NO nitric oxide donors, which shall be discussed in 
more detail in section 1.6, and an example of one such S-NO compound, 
S-nitroso N-Acetyl penicillamine (Soulere at al., 2001), is illustrated in 
figure 10. 
NH
S
O
HO
O
ON   
Figure 10: S-nitroso-N-acetylpenicillamine 
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1.6. S-Nitrosothiols 
 
S-nitrosothiols (RSNOs) have garnered significant interest since the 
discovery of their physiological role in the early 1990‟s (Giustarini at al., 
2003).  It is believed that RSNOs act as a transporter/donor of NO in vivo 
and that they have a potential medical application as NO donors (Williams, 
1999).  The NOS enzymes cause nitrosative chemistry to occur, leading in 
turn to S-nitrosylation, which accounts for the presence of RSNOs in vivo 
(Foster at al., 2003) 
S-nitrosothiols break down to form a disulphide, releasing NO, shown in 
figure 11; L-(-)-glutathione breaking down to form its disulphide, 
releasing NO. 
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Figure 11: NO generated from disulphide formation. 
S-nitrosothiols are generally red or green in colour (Wang at al. 2002), 
with the red colour being attributed to a primary or secondary S-
nitrosothiol such as S-nitrosoglutathione, and the green colour presented 
by a tertiary S-nitrosothiol, such as S-nitroso-N-acetyl penicillamine 
(Hogg, 2000). 
Some RSNOs are relatively stable solids at room temperature (Williams, 
1998), but the nature of the S-N bond means there a number of factors 
which can cleave the bond and cause release of the NO group and the 
majority of RSNOs can thus be unstable at room temperature (Wang at al. 
2002). 
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Three main causes of S-nitrosothiol instability are thermal decomposition, 
photochemical decomposition and decomposition in solution due to trace 
metal ions, such as Cu2+. 
In the case of photodecomposition, S-nitrosothiols are sensitive to UV 
light and in the case of S-nitrosoglutathione irradiation by UV light at the 
absorption maximum at 340nm or 545nm leads to the release of NO and 
thiyl radicals (Sexton at al., 1994).  The thiyl radicals can then react with 
GSNO to form a disulphide and release more NO. 
With thermal decomposition, the thermally labile S-NO bond is cleaved 
homolytically giving an NO radical and a thiyl radical (Wang at al., 2002) 
following which the thiyl radical dimerises to form a disulphide. 
Trace copper ions in solution leads to accelerated decomposition of S-
nitrosothiols and hence NO release is enhanced (Singh at al., 1996).  In 
studies, copper ions bind to GSNO leading to NO release in a method 
which differs from both thermal and photo decomposition in that it 
appears to not decompose via thiyl radical intermediates. 
Amongst different S-nitrosothiols, decomposition can also be affected by 
the NO donor molecule.  Friedman (1977) reports that in thiol groups with 
the thiol attached to a primary carbon, such as in cysteine or glutathione, 
the SH group was far more reactive than the reactivity of the thiol group 
present in penicillamine.  As illustrated below in figure 12, cysteine and 
penicillamine are similar molecules, but the greater steric effect present in 
penicillamine lowers the reactivity of it‟s SH group relative to that of 
cysteine.  Thus it can be expected that S-nitroso penicillamine would be 
less reactive and less likely to decompose than S-nitroso cysteine. 
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S-nitrosothiols such as S-nitrosoglutathione are powerful inhibitors of 
human platelet aggregation (Sogo at al., 2000; Gordge at al., 1998) and 
as such have provided an interesting avenue of research for medicinal 
chemists.  S-nitrosothiols are also potent bronchodilators, and indeed 
deficiencies of RSNOs are seen in near fatal cases of asthma (Gaston at 
al., 1998). 
H2N
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Figure 12: Cysteine (left) and penicillamine. 
As both NO and PUFA demonstrate anti-inflammatory properties in the 
area of heart disease prevention, a conjugate combining the benefits of 
PUFA in diet, the EDRF of NO and the ability to release NO would be 
provide a greater benefit than a normal PUFA treatment. S-nitrosothiols 
are a somewhat unique donor of nitric oxide in that they display the same 
properties of NO. 
 
 
 
 
 
 
 
 
 
 28 
1.7. Nitrated Fatty Acids 
 
A nitrated fatty acid, or nitro lipid, can be described as a polyunsaturated 
fatty acid containing a nitrite group.  The ability of this compound to then 
release nitric oxide in vivo can lead to vasorelaxation (Lima at al., 2005).  
Some nitrolipids have been detected in small quantities in human blood 
(Baker at al., 2009) and there is ongoing research into the field of 
chemical synthesis of novel nitrated fatty acids. 
One proposed mechanism for chemical synthesis of a nitrolipid is 
electrophilic substitution upon reaction of an unsaturated fatty acid and a 
suitable nitrating agent such as nitronium tetrafluoroborate or nitrogen 
dioxide (O‟Donnell at al., 1998) whereby the NO2 group would attack a 
double bond on the fatty acid chain leading to loss of hydrogen and 
attachment of the nitrite group (Manini at al., 2008). An example of this 
type of reaction is demonstrated below in scheme 1. 
 
R1 R2
R1 R2
NO2
NO2BF4
H+
R1 R2
NO2
H
H
 
Scheme 1: Nitronium tetrafluoroborate nitration 
 
Hayama at al. (1982) suggested a method of synthesising conjugated 
nitroalkenes from simple alkenes in a manner that could also be applied to 
polyunsaturated fatty acids.  The method relies upon “electrophilic 
addition of organoselenium reagents across the carbon-carbon double 
bond” to provide nitration of the alkenes, with the nitration occurring in a 
stereospecific manner. 
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Scheme 2 below demonstrates the reaction of the alkene with 
benzeneselenyl bromide followed by nitration via silver nitrate and 
subsequent removal of benzeneselenyl group with hydrogen peroxide and 
reformation of the carbon-carbon double bond. 
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BrR1
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Scheme 2: Organoselenium reaction route. 
Gorczynski (at al., 2006) demonstrated that these two syntheses are 
viable yet not specific as they give regioisomeric mixtures of nitroalkene 
products.  Gorczynski proposed a 9 step synthesis for a regiospecific and 
stereospecific synthesis of (E)-9- and (E)-10-nitrooctadec-9-enoic acid.  
The advantages in a specific compound may be outweighed by the 
difficulties presented by introducing many steps in to the synthetic route.  
One consideration might be that over a nine step reaction the overall yield 
would be low as a result of multiple product purifications and multiple 
analyses at each stage of synthesis. 
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In scheme 3 (adapted from Lima at al., 2005) a possible mechanism for 
nitric oxide release from a nitrolipid decomposing is shown in which the 
nitrolipid isomerises to the nitrite derivative and releases nitric oxide via 
either electron reduction or homolysis. 
R1 R2
NO2
R1 R2
ONO
R1 R2
OH
R1 R2
O
NO NO+ +
Isomerisation
homolysise-/H+
 
Scheme 3: Possible mechanism of NO release. 
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Manini (at al. 2008) proposed another mechanism for NO release from a 
nitrated lipid, which was based on the nef reaction as shown in  scheme 4.  
The nef reaction involves NO release and formation of a ketone from a 
nitroalkane by acid hydrolysis of a nitroalkane salt.  In the modified nef 
reaction of Manini‟s experiment, the nitroalkene is converted to a 
nitronate anion, before transformation into a hydroxynitroso intermediate 
which is then severed to give nitric oxide and an alkene. 
R R1
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Scheme 4: Example of NO release from nitrolipid 
 
The anti-inflammatory properties of nitric oxide and polyunsaturated fatty 
acids are discussed elsewhere in sections 1.4 and 1.5, but there have 
been a range of papers published recently (see below) discussing the anti-
inflammatory characteristics of nitrated polyunsaturated fatty acids. 
Trostchansky at al. (2007) demonstrated the successful nitration of the n-
6 PUFA arachidonic acid.  They then determined the NO release 
capabilities by both electrochemical detection using an NO selective 
electrode and oxyhemoglobin oxidation recording a spectrum in the 
presence of the nitrated lipid.  The results demonstrated that NO was 
released in aqueous media and that the NO released from their nitrolipid 
“induced vasorelaxation in an endothelium independent manner” by 
activation of the soluble guanylate cyclase cycle. 
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Nitrated derivatives of oleic and linoleic acid (Cui at al., 2006)  have been 
studied and shown to be endogenous anti-inflammatory signalling 
mediators which generate anti-inflammatory effects independently of NO 
formation. 
Coles (at al., 2002) suggested an example of similar benefits from a 
nitrated lipid; nitrolinoleate is given which also referred to the vascular 
protective properties via inhibition of platelet activation and by stimulating 
vasorelaxation. This same paper also concludes that the nitrated fatty acid 
“potently blocks multiple proinflammatory responses” and can assuage 
“leukocyte migration and subsequent activation in atherosclerotic lesions” 
and hence display additional vascular protective effects beyond its 
antiplatelet and vasorelaxing effects. 
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2.1 Aims and Objectives 
 
The aim of this project was the synthesis and characterisation of a library 
of novel nitric oxide releasing molecules which could potentially be used 
as nutrapharmaceuticals. 
Nutrapharmaceuticals, or nutraceuticals are known as food products or 
supplements which can provide beneficial medicinal or health related 
effects and can be used as a preventative measure for disease. 
Synthesis of these molecules involved stably attaching a series of low 
molecular weight aminothiols to a polyunsaturated fatty acid before S-
nitrosylation to give a final product.   
Whilst the idea of nitrosation of aminothiols dates back some time (Hart, 
1985), there are no recorded cases of a PUFA-NO releasing S-nitrosothiol 
conjugates being synthesised especially with regard to their use as a 
nutrapharmaceutical. 
Once the library was synthesised and characterised it was intended to 
then examine the nitric oxide releasing properties of the compound via a 
colourimetric test. 
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2.2 Fatty Acids 
 
 
As stated, the aim was the development of a library of compounds to be 
synthesised whereby a saturated and unsaturated fatty acid molecule was 
stably attached to a NO donating linker group.  Initial work involved 
attaching aminothiols to decanoic acid (C10H20O2) followed by nitrosation 
of the appropriate group on the attached linker molecule to give a final 
product.  Once this was achieved, and the synthesised compounds purified 
and characterised, the decanoic acid in the reactions was replaced with an 
unsaturated fatty acid such as oleic acid.  An example of the general 
reaction schemes involved can be seen in scheme 5 and a list of prepared 
compounds is shown in table 1. 
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Scheme 5: Proposed general reaction scheme 
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Table 1: Prepared intermediate compounds  
Acid Linker Group Product 
Decanoic Acid Cysteamine HCl N-decanoyl cysteamine 
Decanoic Acid L-Cysteine Ethyl 
Ester HCl 
N-decanoyl L-cysteine 
ethyl ester 
Decanoic Acid N-Alloc - 
1,4 Butanediamine HCL 
N-Alloc - 1,4 
Butanediamine Decanoate 
Dodecanoic Acid Cysteamine HCl N-dodecanoyl cysteamine 
Dodecanoic Acid L-Cysteine Ethyl 
Ester HCl 
N-dodecanoyl L-cysteine 
ethyl ester 
Oleic Acid Cysteamine HCl N-oleoyl cysteamine 
 
The first stage of the synthesis involved reaction between a relevant fatty 
acid chloride and the specific aminothiol/linker molecule in a basic 
solution.  The purpose of the base was to capture hydrogen chloride 
released in situ from the reaction and to aid dissolution of the linker 
molecules.  Completion of this stage yielded a library of compounds 
consisting of long aliphatic chains attached to a linker molecule via an 
amide bond.  These products were then purified by re-precipitation and 
column chromatography.  Full characterisation was then undertaken using 
analytical mass spectrometry and NMR spectroscopy. 
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After purification and characterisation of the intermediate molecules 
nitrosation was attempted using a range of nitrosating agents and 
methods until a successful nitrosation method was found.  Presence of the 
S-Nitroso or C-Nitroso group on the molecule was confirmed both in 
reaction solution and in isolated solid product by MS and NO release was 
measured using the Griess test, a colourimetric method of determining the 
presence of organic nitrites. 
Past studies have shown (Williams, 1985) that many S-nitrosothiols can 
be very unstable due to the inherent weakness of the S-N bond.  Of the 
range of aminothiols to be used, some have been shown to form stable S-
nitrosothiols (Park and Means, 1989) whilst other aminothiols may form 
less stable S-nitrosothiols but it was hoped the long chain acid would act 
as a stabilising agent, thus preventing the molecule from releasing NO via 
degradation as opposed to biological mediation. 
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2.3 Synthesis of Nitric Oxide Compounds 
 
 
The library of molecules listed in section 2.2 was further developed in the 
attempted synthesis of a series of nitric oxide donors. 
 
It was necessary in the course of the research to investigate a number of 
different nitrosation methods of these molecules. 
 
Whilst the attempted nitrosations were met with varying levels of success, 
S-nitroso cysteamine and S-nitroso octadec-9-enoate were synthesised 
and characterised thus giving both a saturated and unsaturated fatty acid 
linked to a nitric oxide donor.  Unfortunately these molecules both 
displayed instability and decomposed quickly even when stored in the best 
possible conditions – namely, the sample was stored in a darkened round 
bottomed flask which had been purged with nitrogen and was kept in a 
freezer.  This was observed as MS analysis a few days after synthesis 
showed more abundant fragmentation signals for the un-nitrosated 
starting compound and much less abundant fragmentation peaks for the 
target product when compared to MS analysis taken directly after the 
completion of the reactions. 
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2.4 Saturated Fatty Acids 
 
 
The main challenge found in coupling a saturated fatty acid to the 
aminothiols was in choosing a solvent for the reaction.  The primary 
difficulty was the poor solubility of many of the aminothiols, notably L-
cysteine and to a lesser extent DL-homocysteine, in many solvents (such 
as methanol, DCM, DMF, chloroform) and a second issue was the 
extraction of the product from the solvent after the completion of the 
reaction. 
Montalbetti at al., 2005, demonstrated that pyridine could be used as a 
solvent for this type of reaction. Therefore pyridine was adopted into the 
reaction scheme and during experimentation it was found that the 
solubility of all aminothiols increased greatly.  Though MS analysis 
indicated expected product fragmentation signals there was the challenge 
of isolating a solid.  Initial attempts to this end involved use of water to 
precipitate a solid, which proved unfruitful, but the use of toluene enabled 
the solid product to be extracted from solution. 
One disadvantage in using pyridine was that it proved to be a difficult 
solvent to remove completely from the product.  This was in part due to 
the high boiling point making it difficult to remove completely via rotary 
evaporation even with toluene acting as an azeotrope. Also the basic 
nature of pyridine meant it would react with excess HCl in the reaction 
mixture to form the pyridine hydrochloride salt, as demonstrated in 
scheme 6.  This salt required additional washing with water to remove the 
salt.  Unfortunately, both of these processes had the potential to 
encourage disulphide formation. 
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Scheme 6: Reaction scheme involving pyridine solvent. 
After re-precipitation of the extracted solid, NMR analysis displayed proton 
signals not corresponding to the product, implying the presence of 
impurity.  These proton signals were in the aromatic region, implying that 
pyridine remained in the final solid.  Further TLC analysis resulted in two 
spots on the TLC plate, one representing the product and another on the 
baseline indicating a non-starting material.  Unfortunately the resolution 
which was present in the TLC was not able to be replicated with column 
chromatography as the 2 spots co-eluted even using solvents which have 
low polarity. 
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Due to synthetic and product isolation difficulties, it was decided to shift 
focus away from the pyridine solvent based reaction and concentrate on 
finding potential linker molecules which were more readily soluble in 
organic solvents to react with the fatty acids.  The solubility of a range of 
molecules was evaluated and it was found that esters and hydrochloride 
salts of aminothiols were sufficiently soluble in solvent with excess base to 
make reactions viable.   
2.4.1 Synthesis of N-decanoyl cysteamine 
O
N
H
HS
 
Compound 1: N-decanoyl cysteamine. 
Synthesis of N-decanoyl cysteamine (Compound 1, exp 4.1.1) was 
successfully undertaken reacting cysteamine HCl dissolved in DMF solvent 
with triethylamine base with the decanoyl chloride before precipitating a 
solid by addition of deionised water.  On the NMR spectrum, a signal that 
integrated for 1 proton was detected at 7.93 ppm and assigned to the NH 
group.  The methylene next to the C=O was detected at 2.0 ppm 
indicating the presence of an amide bond.  A large broad multiplet 
integrating for 12 protons was centred at 1.2 ppm was assigned to the 
alkyl chain. MS analysis of the isolated solid gave an M-H signal of m/z 
230.0 corresponding to the product molecular weight of 231. 
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2.4.2 Synthesis of N-dodecanoyl cysteamine 
O
N
H
HS
 
Compound 2: N-dodecanoyl cysteamine. 
N-dodecanoyl cysteamine (compound 2, exp 4.1.3) was synthesised 
utilising the same method, substituting lauroyl chloride for decanoyl 
chloride as the acid chloride to be reacted with cysteamine hydrochloride.   
MS analysis of the purified isolated solid displayed signals determined to 
be M+H at m/z 260.2 and M+Cl at m/z 294.2 which corresponded to the 
product molecular weight of 259.  On the NMR spectrum, an NH signal 
integrating for 1 proton was detected at 6.35 ppm and the CH2 next to the 
C=O was detected at 2.15 ppm indicating the presence of an amide bond.  
A 16 proton signal assigned to (CH2)8 was centred at 1.2 ppm confirming 
the presence of the long alkyl chain in the molecule. 
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2.4.3 Synthesis of N-decanoyl L-cysteine ethyl ester 
 
O
N
H
SH
O
O
 
Compound 3: N-decanoyl L-cysteine ethyl ester. 
Whilst L-cysteine had proved to be too insoluble for the purpose of 
previous synthesis attempts, the L-cysteine ethyl ester hydrochloride 
derivative was suitably soluble in a mixture of organic solvents and DiPEA 
base.  As a result, synthesis of N-decanoyl L-cysteine ethyl ester 
(compound 3, exp 4.1.2) was completed by reaction of decanoyl chloride 
with L-cysteine ethyl ester HCl.  MS analysis of the purified isolated solid 
displayed signals at m/z 302.2 (M-H) and m/z 338.2 (M+Cl) 
corresponding to the product molecular weight of 303.  NMR analysis 
detected a signal, assigned to the NH, which integrated for 1 proton at 8.3 
ppm, the CH near the peptide bond at 4.5 ppm and the CH2 next to the 
CO on the amide bond was detected at 2.2ppm. The CH3 with a signal 
integration showing 3 protons of the alkyl chain was seen at 0.85 ppm 
whilst the CH3 of the ethyl ester, a triplet signal integrating for 3 protons, 
was seen at 1.23 ppm. 
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2.4.4  Synthesis of N-dodecanoyl L-cysteine ethyl ester 
O
N
H
SH
O
O
 
Compound 4: N-dodecanoyl L-cysteine ethyl ester. 
N-dodecanoyl L-cysteine ethyl ester (compound 4, exp 4.1.4) was 
synthesised utilising the same technique, replacing decanoyl chloride with 
lauroyl chloride. NMR analysis detected the NH signal integration for 1 
proton at 6.4 ppm, the CH near the amide bond at 4.8 ppm and the CH2 
next to the CO on the amide bond was detected at 2.2 ppm, integrating 
for 2 protons.   The CH3 , integrating for 3 protons, of the alkyl chain was 
seen at 0.8 ppm whilst the CH3 of the ethyl ester was seen at 1.2 ppm, 
with a signal integration representing 3 protons. MS analysis of the 
product solid displayed a signal at m/z 367.2 for M+Cl corresponding with 
the expected product molecular weight of 333.  
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2.4.5 Synthesis of N-Alloc – 1,4 Butanediamine Decanoate 
H
NO
O
N
H
O
 
Compound 5: N-Alloc 1,4 butanediamine decanoate. 
N-Alloc 1,4 butanediamine hydrochloride was reacted with decanoic acid 
as the acid chloride route was deemed unsuitable in this case.  Instead, a 
peptide coupling cocktail, consisting of TBTU, Hobt and DiPEA, was utilised 
to create an amide bond in the synthesis of N-Alloc 1,4 butanediamine 
decanoate (compound 5, exp 4.1.5).  Following purification and 
characterisation, the product was ready for nitrosation attempts.  The 
product was confirmed by MS analysis, with MS peaks at m/z 327.2 
(M+H) and m/z 361.2 (M+Cl) corresponding to the expected product 
molecular weight of 326.  NMR analysis showed the NH signal integration 
for 1 proton at 4.7 ppm and the CH2 next to the CO of the amide bond at 
2.2 ppm, demonstrating the formation of a peptide bond between 
decanoic acid and N-Alloc 1, 4 butanediamine HCl.  On the N-alloc moiety, 
the NH signal integration for 1 proton was seen at 5.6 ppm and the C=CH 
was seen at 5.9 ppm, integrating for 1 proton. 
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Attempts were made to react penicillamine with a saturated fatty acid 
chain using both the acid chloride route and the peptide coupling reaction 
route. Reactions involving penicillamine and decanoyl chloride yielded no 
positive results, with MS analysis only detecting peaks assignable to the 
starting materials. Another method was attempted, using a mixed 
anhydride synthesis which had shown some success as demonstrated by 
Megson (at al., 1999).  Initial attempts in recreating this method showed 
some success (with MS analysis detecting an expected product 
fragmentation signal) although a pure solid could not be isolated, due to 
time constraints and no way of progressing the reaction to an unsaturated 
fatty acid chain, it was decided to not pursue this reaction route. 
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2.5 Unsaturated Fatty Acids 
 
As the acid chloride route employed for the generation of compounds 1-5 
as described in section 2.4 had yielded some positive results, synthesis of 
an unsaturated fatty acid-linker conjugate via the acid chloride synthetic 
route using oleoyl chloride was undertaken.  Oleoyl chloride (pictured 
below in figure 15) is an eighteen carbon chain unsaturated fatty acid with 
a carbon carbon double bond at the 9 position. 
O
Cl
 
Figure 15: Oleoyl chloride 
 
Synthetic attempts were made to link penicillamine, L-cysteine ethyl ester 
HCl and cysteamine HCl with oleoyl chloride.  The most successful of these 
syntheses was in using cysteamine HCl. Cysteamine HCl was dissolved in 
a solution of DMF and triethylamine before the drop wise addition of oleoyl 
chloride.  After the reaction was allowed to proceed to completion, 
deionised water was added to precipitate a solid.  This was then purified 
and characterised to give N-oleoyl cysteamine (Compound 6, Exp4.1.6).  
MS analysis confirmed the expected molecular weight of 341 with signals 
corresponding to M-H at m/z 340.2 and M+Cl at m/z 376.2.  NMR analysis 
displayed the NH integration signal representing 1 proton at 8.0 ppm, with 
the CH2 next to the amide bond seen at 2.7 ppm representing 2 protons.  
The hydrogens of the C=C of the alkyl chain were seen at 5.35 ppm.  
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O
NH
HS
 
Compound 6: N-oleoyl cysteamine 
 
Whilst attempts to create a saturated fatty acid - penicillamine conjugate 
had been unsuccessful, the reaction between penicillamine and oleoyl 
chloride proved more successful, yielding a solid which displayed signals 
of m/z 414.2 (M+H) and m/z 412.6 (M-H) under MS analysis conforming 
to the expected product molecular weight of 413. 
However, investigation using NMR showed a mixture of signals indicating 
the presence of 2 molecules very similar in structure present in the solid. 
Signals were interpreted which would account for the long alkyl chain, 
there were two broad multiplets in close proximity (at δ 1.35 and 1.40) 
which could have represented the alkyl chain and similarly two triplets (at 
δ 1.1 and 1.2) which would likely represented the CH3.  There were also 
signals which indicated the presence of NH (δ 6.7), COCH2 and HC=CH (δ 
5.35) which is a strong indicator that the spectrum showed a mixture of 
two compounds similar in structure 
 
As acid chlorides are very reactive and thus lack specificity, it is believed 
that the mixture in the solid could be as the acid chloride has attached to 
both the NH2 and the OH sites on penicillamine in equal amounts.  A 
solution to this could be to protect the OH group, however due to time 
constraints; it was not possible to focus on this avenue in the course of 
the research. 
 
NH
HS
O
HO
O  
Figure 14: Penicillamine octadec-9-enoate 
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2.6  Nitric Oxide Compounds 
 
In order to generate a library of nitrosated compounds (from compounds 
1-6) a number of different methods of nitrosation were considered and 
attempted, with varying levels of success. 
 
2.6.1 Sodium Nitrite Technique 
Initial attempts were made to nitrosate these compounds by addition of 
sodium nitrite (Hart, 1985) as described in 4.3.4 as sodium nitrite is a 
common nitrosating agent.  After a series of attempted nitrosations no 
sign of nitrosated product was detected by MS analysis so it was decided 
to move on to other nitrating agents.   Nitrosation attempts by this 
method of N-decanoyl cysteamine and N-decanoyl L-cysteine ethyl ester 
yielded no success, as MS analysis displayed no sign of product, with 
fragmentation signals only indicating starting materials present. 
 
2.6.2 Nitronium Tetrafluoroborate Technique 
Nitronium tetrafluoroborate was deemed to be a suitable nitrating agent in 
the case of N-alloc 1, 4 butanediamine decanoate, which has a C=C bond 
as opposed to an S-H group as the proposed site of nitrosation.  It was 
hoped that nitronium tetrafluoroborate could provide successful 
nitrosation as it had been used in nitrosation of C=C bonds (O‟Donnell at 
al., 1999) successfully as reported in literature.  Nitrosation attempts 
were carried out, as described in section 4.2.5, by addition of one 
equivalent of nitronium tetrafluoroborate to the fatty acid-linker conjugate 
dissolved in organic solvent.  Analysis both during and after this reaction 
showed this method of nitrosation to be unsuccessful as MS analysis failed 
to show any expected product signal, instead only providing signals which 
corresponded to the molecular weight of the starting material. 
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2.6.3 Tert-Butyl Nitrite Technique 
Other methods of nitrosation were explored, one of which was nitrosation 
by tert-butyl nitrite (Koley at al., 2009).  Initial experimentation using one 
equivalent to nitrate proved unsuccessful so it was decided to add an 
excess of tert-butyl nitrite. 
 
N-decanoyl cysteamine was dissolved in a small amount of DCM and a 
drop of HCl in a darkened flask, cooled with ice and purged with nitrogen.  
To this was added five equivalents of tert-butyl nitrite, following which the 
reaction was observed by TLC and MS.  Colour changes were observed 
and MS analysis displayed the expected product signals for S-nitroso N-
decanoyl cysteamine (compound 7, exp 4.2.1) with a signal of (M-H) m/z 
259.0 corresponding to the molecular weight of 260. 
O
N
H
S
N
O
 
Compound 7: S-nitroso N-decanoyl cysteamine 
 
This method was also applied to N-oleoyl cysteamine (compound 8, 
below) as described in exp4.2.2 and also yielded success in providing a 
nitrated product, with MS analysis indicating a signal of M+H at m/z 
372.2, corresponding to the product molecular weight of 371. 
O
NH
S
N
O
 
Compound 8: S-nitroso N-oleoyl cysteamine 
 
In both cases the DCM solvent was evaporated to give a solid.  The 
evaporation of the solvent was performed at low temperatures due to the 
inherent lability of the S-N bond. 
Unfortunately nitrosation attempts of the other compounds using this 
method proved to be unsuccessful. 
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2.6.4 Nitric Oxide „Fuming‟ Technique 
Another method attempted was by „fuming‟ (Mazzei, 2001) nitrous oxide 
fumes directly into a solution containing N-oleoyl cysteamine in organic 
solvent.  This was performed by dropping concentrated HCl directly onto 
sodium nitrite pellets and directing the flow of NO gas given off to 
bubbling through the N-oleoyl cysteamine solution.  MS analysis 
determined that this was also an effective method of nitrating the sample 
as indicated by the presence of a signal (M+Cl) at m/z 404.2 
corresponding to the expected product mass. Proton NMR analysis of the 
product showed the absence of the C=C hydrogen peaks, which had been 
present in the starting material at δ: 5.35, indicating that the fuming 
method of nitrosation was a stronger nitrosation method than the tert-
butyl nitrite method and was likely also nitrating the C=C bond on the 
fatty acid chain in addition to the S-H group on the cysteamine linker. 
 
2.6.5 Summary of Results 
Nitric oxide containing molecules were successfully synthesised using a 
range of techniques and were characterised by NMR and MS.  Some 
nitrating agents proved more successful than others and the created 
compounds are displayed below in table 2. 
 
Table 2: Synthesised NO containing compounds. 
 
Starting compound Nitrating agent Product 
N-decanoyl cysteamine Tert-butyl nitrite S-nitroso N-decanoyl 
cysteamine 
N-oleoyl cysteamine Tert-butyl nitrite S-nitroso N-oleoyl 
cysteamine 
 
N-oleoyl cysteamine NO fuming method S-nitroso N-oleoyl 
cysteamine 
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2.7 Griess Reagent 
 
The Griess reaction is a means by which to detect organic nitrites 
originally developed in 1879 as a colourimetric test (Griess, 1879).   
During the reaction, the Griess reagent (a solution containing sulfanilic 
acid and N-(1-naphthyl)-ethylenediamine dihydrochloride(NEDD))  
undergoes a diazotisation reaction with nitric oxide to form a diazo 
compound, which is a red azo dye. The reaction is shown in scheme 7 
(adapted from Nirode, 2006).  The Griess reaction can be viewed as a 
simple colourimetric test, with positive nitrite presence indicated by 
formation of a red colour. 
 
H2N
N2
+
N
N
SO2NH2
NH2
N
O
SO2NH2
SO2NH2
N2O3
- H2O
NO2
+
H2NSO2
NH(CH2)2NH2
NEDD
 
Scheme 7: Griess reaction 
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Demonstrated below in figure 15 are three sample vials of Griess reagent 
(1ml) to which has been added, from left to right; 1ml methanol (blank 
control sample), S-nitroso N-oleoyl cysteamine as nitrosylated via the 
fuming method and finally S-nitroso N-oleoyl cysteamine as nitrosylated 
by reaction with tert-butyl nitrite. 
 
 
Figure 15: Photograph taken shortly after the respective samples were added to the Griess reagent.   
 
Following this, the sample tubes were incubated at 37oC for 15 minutes. 
 
It was observed, figure 16, that the control sample remained colourless 
whilst both S-Nitroso N-oleoyl cysteamine samples had developed a 
pink/red colour indicating that a red azo dye had been formed as a result 
of the presence of NO in both solutions.  Thus it can be inferred that S-
Nitroso N-oleoyl cysteamine was releasing nitric oxide in the presence of 
the Griess reagent. 
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Figure 16: Griess samples after incubation period. 
 
The observations made from all Griess testing of synthesised potential NO 
donor compounds are displayed in Table 3. 
 
Table 3: Observations of Griess testing 
 
Compound observed Colour change noted 
S-nitroso N-decanoyl cysteamine Pinkish red colour change noted 
S-nitroso cysteamine 
octadec-9-enoate 
 
Pinkish red colour change noted 
S-nitroso cysteamine 
octadec-9-enoate 
 
Pinkish red colour change noted 
Blank methanol control sample No change 
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3.0 Conclusions and Future Work 
 
 
During this research a number of methods were used to synthesise fatty 
acid chains attached to linker molecules.  From this work a small library of 
compounds was synthesised and work was undertaken to nitrate the 
linker molecules via a range of nitrosation methods. 
 
As a result both S-nitroso cysteamine and S-nitroso octadec-9-enoate 
were synthesised and characterised.  The ability of these molecules to 
release nitric oxide was then qualitatively studied via the Griess reaction, 
which demonstrated that both molecules released NO.  When compared to 
a blank, both molecules dissolved in methanol and Griess reagent 
developed a red colour whilst the blank remained colourless. 
 
Due in part to the inherent instability of S-nitrosothiols in general, both of 
the synthesised nitric oxide donors exhibited poor stability and short shelf 
life, although a full decomposition study was not undertaken in this 
research.  As a result, it is unlikely that either of the synthesised 
molecules would have much practical application. 
 
As an avenue for future study, it should be noted that the synthesis of a 
penicillamine-unsaturated fatty acid conjugate could be completed with 
more time to dedicate to the separation of the product mixture alluded to 
in section 3.1.  With the steric effect exhibited by penicillamine, it is likely 
a successfully created and nitrated molecule would be relatively stable. 
 
Further study could also focus on different types of NO donors, such as 
transition metal NO donors, C-NO donors or O-NO donors (Martelli at al., 
2006). Replacing the S-NO spacer molecules with C-NO spacer molecules 
would likely give a more stable final compound than those synthesised in 
the course of this research.  Aiming towards a final product with more 
likely stability than that typically seen in RSNOs could result in a library of 
more stable final NO donating compounds. 
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4.0 Experimental 
 
4.0.1 Methods used to characterise synthesised compounds 
 
NMR 
1H NMR spectra obtained using a Bruker WP250 (400MHz) NMR 
spectrometer.   
 
MS 
Low resolution electrospray mass spectra recorded using an Agilent 
Technologies 6130 Quadruple LC/MS instrument (mass range m/z 4000, 
maximum resolution 3000).  Samples were dissolved in methanol prior to 
analysis. 
 
Chromatography 
Thin layer chromatography performed on polygram Sil G UV 0.2mm silica 
gel plates.  TLC plates were stained using an iodine tank to visualise 
spots. Solvent used was Methanol:water (9:1) 
Column chromatography used silica gel and solvent used was 
hexane:chloroform (9:1 and 99:1) 
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4.1.1 Synthesis of N-decanoyl cysteamine 
O
N
H
HS
1
2
3
4
5
6
7
8
9
10
11
12
13
 
To a solution of cysteamine hydrochloride (0.5g, 4.4mmol) dissolved in 
DMF (5ml) was added triethylamine (0.61ml, 4.4mmol).  This mixture was 
allowed to stir for 20 minutes before decanoyl chloride was (0.91ml, 
4.4mmol) added dropwise.  The reaction was allowed to proceed for 2 
hours, after which time 5ml deionised H2O was added to precipitate a 
solid.  The solid was filtered off and washed with 5ml cold deionised H2O, 
followed by 5ml of ether.  The solid was then dried in a vacuum oven for 2 
hours prior to characterisation by NMR and MS. 
Found: 
Yield: 52.6% 
MS: m/z at 230.0 (100%) (M-H) 
1H NMR: (DMSO) δ: 0.8(t, 3H, CH3)1; δ: 1.2 (bm, 12H, (CH2)6)2-7; δ: 
1.42 (t, 2H, CH2)8; δ: 2.0 (t, 2H, CH2)9; δ: 2.7 (bm, 2H, CH2)12; δ: 3.23 
(m, 2H, CH2)11; δ: 7.93 (t, 1H, NH)10 
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4.1.2 Synthesis of N-decanoyl L-cysteine ethyl ester 
O
N
H
SH
O
O
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
 
 
L-cysteine ethyl ester hydrochloride(1g, 5.4mmol) was dissolved in a 1:1 
mixture of dichloromethane and ethyl acetate (10ml:10ml), to this 
solution was added DiPEA (diisopropylethlamine) (18.6 ml, 1.025mol).  
The mixture was allowed to stir for 30 mins, upon which time decanoyl 
chloride (5.3mmol, 1.34ml) was added.  After 3 hours, the reaction 
solution was rotary evaporated to dryness. The solid was then heated to 
60oC then reprecipitated to purify and dried at 50oC in a vacuum oven for 
2 hours before being analysed by NMR and MS. 
Found: 
Yield: 42.3% 
MS: (-) m/z 302.2 (100%) (M-H); 338.2 (18%) (M+Cl) 
1H NMR: (DMSO) δ: 0.85(t, 3H, CH3)1; δ: 1.23(t, 3H, CH3)15; δ: 1.4 (bm, 
12H, (CH2)6)2-7; δ: 1.49 (t, 2H, CH2)8; δ: 2.2 (t, 2H, CH2)I ; δ: 2.9 (m, 
1H, CH2)12; δ: 3.1 (m, 1H, CH2)12; δ: 4.1 (q, 2H, CH2)14; δ: 4.5 (m, 1H, 
CH)11; δ: 8.3 (d, 1H, NH)10 
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4.1.3 Synthesis of N-dodecanoyl cysteamine 
O
N
H
HS
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
 
Cysteamine hydrochloride (1g, 8.8mmol) was dissolved in a solution of 
DMF (20ml), triethylamine (2.45ml, 17.6mmol) and allowed to stir for 20 
mins.  After this time lauroyl chloride (2.04ml, 8.8mmol) was added 
dropwise and the reaction was then allowed to proceed for 2 hours.  After 
this time deionised water (20ml) was added and a solid precipitate, which 
was then filtered off before being dissolved in ethanol at 60oC and allowed 
to reprecipitate then vacuum oven dried at 40oC for 2 hours.  Following 
drying, the solid was characterised by MS and NMR. 
Found: 
Yield: 25.7% 
MS: (+) m/z 260.2(100%) (M+H); 282.0 (M+Na) (12%), (-) m/z 258.2 
(55%) (M-H); 294.2 (35%) (M+Cl) 
1H NMR: (CDCl3) δ: 0.8(t, 3H, CH3)1; δ: 1.2 (bm, 16H, (CH2)8)2-9; δ: 1.6 
(t, 2H, CH2)10; δ: 2.15 (t, 2H, CH2)11; δ: 2.75 (t, 2H, CH2)14; δ: 3.5 (m, 
2H, CH2)13; δ: 6.35 (t, 1H, NH)12 
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4.1.4 Synthesis of N-dodecanoyl L-cysteine ethyl ester 
O
N
H
SH
O
O
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
 
L-cysteine ethyl ester hydrochloride(2g, 0.0108mol) was dissolved in a 
1:1 mixture of dichloromethane and ethyl acetate (15ml:15ml), to this 
solution was added DiPEA (30 ml).  The mixture was allowed to stir for 30 
mins, upon which time lauroyl chloride (1.45ml, 0.0108mol) was added.  
After 3 hours, the reaction solution was rotary evaporated to dryness. The 
solid was then heated at 60oC and allowed to reprecipitate to purify and 
then dried at 50oC in a vacuum oven for 2 hours before being tested by 
NMR and MS. 
Found: 
Yield: 28.6% 
MS: (-) m/z 367.2 (100%) (M+Cl) 
1H NMR: (CDCl3) δ: 0.8 (t, 3H, CH3)1; δ: 1.2 (t, 3H, CH3)17 δ: 1.26 (bm, 
16H, (CH2)8)2-9; δ: 1.6 (t, 2H, CH2)10; δ: 2.2 (t, 2H, CH2)11; δ: 3.05 (m, 
1H, CH2)14; δ: 3.15 (m, 1H, CH2)14; δ: 4.2 (t, 2H, CH2)16; δ: 4.8 (m, 
1H, CH)13; δ: 6.4 (d, 1H, NH)12 
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4.1.5 Synthesis of N-Alloc 1, 4 Butandiamine Decanoate 
H
NO
O
N
H
O
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18  
To a solution of DMF (5ml) and DiPEA (0.17ml, 9.6mmol) was added  N-
Alloc 1,4 butandiamine hydrochloride (0.2g, 9.6mmol), which was allowed 
to stir for 20 minutes.  A second solution comprising of  a mixture of 
decanoic acid (0.1651g, 9.6mmol), TBTU (0.6154g, 19.2mmol), Hobt 
(0.2589g, 19.2mmol) and DiPEA (0.68ml, 38.3mmol) in DMF (2ml) was 
prepared and added to the first reaction solution.  The reaction was 
allowed to proceed for 2 hours (with TLC monitoring). Upon completion, 
the solution was evaporated to dryness and the resultant solid heated in 
ethanol at 60oC and allowed to reprecipitate then dried in a vacuum oven 
at 50oC for 2 hours before being tested by NMR and MS. 
Found: 
Yield: 66.1% 
MS: (+) m/z 327.2 (100%) (M+H), (-) m/z 361.2 (100%) (M+Cl) 
1H NMR: (CDCl3) δ: 0.8(t, 3H, CH3)1; δ: 1.18 (bm, 12H, (CH2)6)2-7; δ: 
1.49 (t, 4H, CH2, CH2)12, 13; δ: 1.51 (t, 2H, CH2)8; δ: 2.2 (t, 2H, CH2)9; 
δ: 3.3 (d, 2H, CH2)11; δ: 3.4 (d, 2H, CH2)14; δ: 4.5 (d, 2H, CH2)16; δ: 
4.7 (d, 1H, NH)10; δ: 5.2 (d, 2H, CH2)18; δ: 5.6 (d, 1H, NH)15; δ: 5.9 
(m, H, CH)17 
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4.1.6 Synthesis of N-oleoyl cysteamine 
O
NH
HS
12
3
4
5
6
7
8
910
11
12
13
14
15
16
17
18
19
2021
 
Cysteamine hydrochloride (1g, 8.8mmol) was dissolved in a solution of 
DMF (20ml), triethylamine (4.91ml, 35.2mmol, 4 eq) and DiPEA (1.53 ml, 
8.8mmol) and allowed to stir for 20 mins.  After this time of oleoyl 
chloride (2.91 ml, 8.8mmol) was added dropwise and the reaction was 
then allowed to proceed for 2 hours.  After this time deionised water 
(20ml) was added to precipitate a solid, which was filtered off before 
being reprecipitated from ethanol at 60oC and vacuum oven dried at 40oC 
for 2 hours.  Following drying, the solid was tested by MS and NMR. 
Found: 
Yield: 42.8% 
MS: (-) m/z 340.2 (15%) (M-H), 376.2 (100%) (M+Cl) 
1H NMR: (DMSO) δ: 0.85(t, 3H, CH3)1; δ: 1.35 (bm, 20H, (CH2)6 and 
(CH2)4)2-7, 12-15; δ: 1.49 (t, 2H, CH2)16; δ: 1.9 (t, 2H, CH2)17; δ: 2.1 
(4H, 2xCH2)11,8; δ: 2.7 (t, 2H, CH2)20; δ: 3.4 (t, 2H, CH2)19; δ: 5.35 (t, 
2H, CH and CH)9,10; δ: 8.0 (t, 1H, NH)1 
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4.2.1 Nitrosation of N-decanoyl cysteamine 
O
N
H
S
N
O
1
2
3
4
5
6
7
8
9
10
11
12
 
N-decanoyl cysteamine (0.05g, 2.16mmol) was added to a solution of 
MeOH (5ml) and allowed to stir. In a separate flask, conc. HCl was added 
dropwise directly onto NaNO2 and the resultant nitrous fumes were 
introduced into the reaction solution and allowed to bubble through.  The 
reaction was observed by TLC and MS analysis was performed to 
determine presence of S-nitroso-N-decanoyl cysteamine. Solvent was 
removed via rotary evaporation at 30oC to give a white solid powder. 
Found: 
MS: (-) m/z (100%) (M+Cl) 
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4.2.2 Nitrosation of N-oleoyl cysteamine by tert-Butyl Nitrite 
O
NH
S
O
N
12
3
4
5
6
7
8
910
11
12
13
14
15
16
17
18
19
20
 
N-decanoyl cysteamine (0.05g, 1.5mmol) was dissolved in anhydrous 
DCM (3ml) and 2N HCl (2 eq, 0.01ml) and allowed to stir on ice in a 
darkened 25ml round bottomed flask for 15 minutes.  An excess 
(7.5mmol, 0.087ml) of tert-butyl nitrite was added to this solution, 
immediately following which Nitrogen gas was purged through the sample 
flask.  A slight colour change from colourless to a mild yellow was 
observed upon addition of nitrating agent.  The solution was dried at 30oC 
to give a solid powder, which was then analysed by NMR and MS. 
Found: 
MS: (+) m/z at 372.2 (100%) (M+H), (-) m/z 405.2 (100%) (M+Cl) 
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4.2.3 Nitrosation of N-oleoyl cysteamine by ‘fuming’ method 
O
NH
S
O
N
 
N-oleoyl cysteamine (0.05g, 1.5mmol) was added to a solution of MeOH 
(5ml) and allowed to stir. In a separate flask, conc. HCl was added 
dropwise directly onto NaNO2 and the resultant nitrous fumes were 
directed into the reaction solution and allowed to bubble through.  The 
reaction was observed by TLC and MS analysis was performed to 
determine presence of S-nitroso-N-oleoyl cysteamine. Solvent was 
stripped off under mild heat rotary evaporation to give a white solid 
powder. 
Found: 
MS: (-) m/z 404.2 (100%) (M+Cl), (+) m/z 408.2 (100%) (M+K) 
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4.2.4 Nitrosation of N-oleoyl cysteamine by Sodium Nitrite 
N-oleoyl cysteamine (0.05g, 1.5mmol) was added to a solution of MeOH 
(5ml) and allowed to stir.  One equivalent of sodium nitrite (0.01g) was 
dissolved in MeOH (3ml) and added dropwise to the reaction solution. 
Reaction was observed by MS and TLC but analysis did not determine the 
presence of S-Nitroso N-oleoyl cysteamine. 
 
4.2.5 Nitrosation of N-oleoyl cysteamine by Nitronium 
Tetrafluoroborate 
N-oleoyl cysteamine (0.05g, 1.5mmol) was added to a solution of DCM 
(4ml) and allowed to stir.  Nitronium tetrafluoroborate (0.0194g, 
1.5mmol) was added in one portion to the reaction solution. 
Reaction was observed by MS and TLC but analysis did not determine the                        
presence of S-nitroso N-oleoyl cysteamine. 
The reaction was abandoned when it became apparent the intended 
product was not being formed. 
4.3.1 Griess testing of Nitrosylated compounds 
NO containing product (S-nitroso N-oleoyl cysteamine, 5mg; S-nitroso N-
decanoyl cysteamine, 5mg) was dissolved in 1ml of methanol.  To this 
was added 1ml of the Griess reagent. For comparison purposes, a sample 
of 1ml blank methanol was also mixed with 1ml Griess reagent.  The 
initial colour was noted and then the sample was incubated at 60oC for 15 
minutes.  Once removed, any development of colour changes (thus 
indicating red azo dye formation and thus NO release) was noted. 
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